SCHEMBL5536747

SCHEMBL5536747

[CH2]CC(=O)Nc1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 3/20 0.46
GAA P10253 3/20 0.42
HPGD P15428 2/20 0.41
CNR2 P34972 1/20 0.41
PTGS2 P35354 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
F2R P25116 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540922 0.86 POLB (0.47) L3MBTL1POLBGAAHPGDPTGS2
SCHEMBL5537133 0.80 POLB (0.49) L3MBTL1POLBGAAHPGDMEN1
SCHEMBL2093273 0.78 L3MBTL1 (0.45) L3MBTL1POLBGAAHPGDPTGS2
SCHEMBL2099201 0.76 L3MBTL1 (0.43) L3MBTL1HPGDPTGS2MEN1KMT2A
SCHEMBL5543551 0.76 KCNJ11 (0.49) L3MBTL1POLBGAAMEN1KMT2A
SCHEMBL17316256 0.76 KIF11 (0.45) L3MBTL1POLBGAAPTGS2MEN1
SCHEMBL2095561 0.73 TRPA1 (0.46) L3MBTL1POLBGAAHPGDMEN1
SCHEMBL10797916 0.72 L3MBTL1 (0.46) L3MBTL1POLBGAAHPGDPTGS2
SCHEMBL10348347 0.72 PARP1 (0.49) L3MBTL1GAAHPGDMEN1KMT2A
SCHEMBL10668835 0.71 SMN1; SMN2 (0.48) L3MBTL1POLBHPGDPTGS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118344384-A Compounds and uses thereof 丹诺医药(苏州)有限公司 2024-07-16 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 L3MBTL1 1931/4885POLB 1637/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.